Key Takeaways
- Alaunos Therapeutics (NASDAQ:TCRT) traded at USD 3.68, up 21.45%, during the October 14, 2026 morning session. Volume reached 39.862 million shares, one day after an October 13 Form 8-K reported the Merger with Velaris Therapeutics had been completed.
- A private Placement of approximately USD 350 million at USD 1.4357 per share was expected to close on October 14, 2026. Investors led by Fairmount were expected to contribute about USD 100.0 million.
- Merger consideration included 105,286 Series B and 33,054 Series C non-voting convertible preferred shares. Subject to conditions, each preferred share can convert into 1,000 common shares.
- A stockholder vote is planned on conversion of the preferred securities, changing the corporate name to Velaris Therapeutics, Inc., increasing authorized shares and implementing a reverse split. The reverse-split ratio had not yet been set.
The Merger and Capital Raise Reshape the Company
The October 13, 2026 Form 8-K explained that Alaunos’ two-step merger did not require approval from its stockholders. The concurrent placement includes 687,789 common shares and 243,063 Series C Preferred Shares at USD 1,435.70 each, with proceeds earmarked for Velaris research programmes, Working Capital and general corporate use. Fairmount’s Peter Harwin joined the board when the transaction closed. If stockholders approve conversion, Velaris representatives and nominees of the lead investors will control four of the five board seats. A resale-registration statement is due within 30 days of the financing close. The filing also said Series A-1 and Series A-2 holders had agreed to convert to common stock before the record date, simplifying that part of the Capital Structure ahead of the vote.
Preferred Conversion Could Greatly Expand the Common Share Base
The merger and placement preferred securities would convert into approximately 381 million common shares, based on arithmetic using the 8-K terms. That figure is much larger than the existing common share count. Nasdaq stockholder approval is required for conversion; if approval is not secured, holders may be entitled to cash settlement beginning six months after issuance. Each holder can choose a beneficial-ownership cap from 0% to 19.99%, and insiders are subject to a 180-day lock-up. Since a reverse split is also under consideration, per-share comparisons before and after a vote may be misleading. The as-converted stake of the new investors is substantially larger than the legacy holders’ stake. Non-voting preferred securities can permit large investors to provide capital without immediately crossing Nasdaq ownership thresholds, but later conversion would shift a large share of voting power.
Shareholder Approval and Clinical Execution Are Key Risks
Investors still face uncertainty around stockholder consent, the reverse-split ratio and the company’s early-stage clinical programme. Paragon has rights to revert licences if stockholders’ Equity does not exceed USD 200 million at a specified quarter-end. CEO Holger Weis may be eligible for a retention payment tied to completing ALN1003 development by July 30, 2027. The next items to watch are confirmation of the placement close, the proxy statement and meeting date, and the next quarterly filing; its date had not been announced at publication. A 21.45% gain on 39.862 million shares after a Reverse merger may reflect investor sentiment, not evidence of sustained demand. This is not Investment advice.
What the Transaction Means for Existing Holders
Alaunos Therapeutics (NASDAQ:TCRT) gained 21.45% after its October 13, 2026 filing confirmed the merger with Velaris Therapeutics and described financing of about USD 350 million. The large convertible-preferred issuance, pending reverse split and planned stockholder vote leave important questions about dilution and execution. The next major event is the stockholder meeting, whose date had not been announced. This is not investment advice.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...